Anzeige
Mehr »
Donnerstag, 16.10.2025 - Börsentäglich über 12.000 News
Jetzt folgt der nächste Coup - CiTech mit Lettland jetzt auf Europas Verteidigungsbühne
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
16.10.25 | 19:10
37,275 Euro
-0,48 % -0,180
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
37,15537,27519:11
37,15537,27519:11

Aktuelle News zur BRISTOL-MYERS SQUIBB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:54BMS acquires Orbital Therapeutics in $1.5bn deal8
13:02Bristol-Myers Squibb Company: HopeHealth Launches Phase 3 Clinical Trial Site To Advance Lupus Research With Support From Bristol Myers Squibb148First HopeHealth Clinical Trial Marks Major Milestone for Access to Medical Research in Rural South CarolinaOriginally published on HopeHealth NORTHAMPTON, MA / ACCESS Newswire / October 16, 2025 /...
► Artikel lesen
MiBristol-Myers Squibb Company: Bristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate Foundation189New contribution will help expand access to care by strengthening the Patient Advocate Foundation's capacity to deliver essential services and case management to vulnerable patients NORTHAMPTON, MA...
► Artikel lesen
DiKI-Allianz gegen ALS: Insitro und Bristol Myers Squibb erweitern Kooperation20
Diinsitro, Bristol Myers Squibb extend ALS collaboration with AI focus15
DiCabaletta picks up the pace with new commercial chief from Legend, Celgene7
DiSystImmune to Receive $250M BMS Milestone7
BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln
DiBMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?34
DiBristol-Myers Squibb Company: Every Word Matters: The Next Chapter of Our Universal Patient Language152Originally published on BMS.com in recognition of Health Literacy Month, the following article highlights how Bristol Myers Squibb's Universal Patient Language (UPL) program is advancing clearer, more...
► Artikel lesen
Di11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region306Bristol Myers Squibb employees in Riyadh and Dubai collaborated with local PAGs to host patient-centered toy-making workshops. These dedicated efforts resulted in handmade toys...
► Artikel lesen
DiWhat to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report33
MoBMS cooks up schizophrenia stigma-busting initiative with 'Top Chef' judge Gail Simmons17
MoBMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition6
MoWill the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?21
MoBristol Myers Squibb to Present Data at ESMO 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types226Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held...
► Artikel lesen
MoSystImmune To Receive One-time Payment Pursuant To Agreement With Bristol Myers260NEW YORK CITY (dpa-AFX) - SystImmune announced the treatment of the first patient in the IZABRIGHT-Breast01 study, a global Ph2/3 registrational study of izalontamab brengitecan, or iza-bren...
► Artikel lesen
MoSystImmune erhält Meilensteinzahlung von 250 Millionen US-Dollar von Bristol Myers Squibb10
MoSystImmune receives $250 million milestone payment from Bristol Myers Squibb7
MoSystImmune, Inc.: SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration53REDMOND, Wash., Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the...
► Artikel lesen
SaNotable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus20
Weiter >>
424 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,2,16